Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.
2.
3.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

4.

Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.

J Immunol. 2007 Dec 1;179(11):7295-304.

5.

Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.

Heier I, Hofgaard PO, Brandtzaeg P, Jahnsen FL, Karlsson M.

Clin Exp Immunol. 2008 May;152(2):381-7. doi: 10.1111/j.1365-2249.2008.03642.x. Epub 2008 Mar 12.

6.

Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.

Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C.

J Immunol. 2007 Mar 1;178(5):2883-92.

7.

Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.

Wang S, Jiang J, Guan Q, Lan Z, Wang H, Nguan CY, Jevnikar AM, Du C.

Transpl Immunol. 2008 May;19(2):93-102. doi: 10.1016/j.trim.2008.03.004. Epub 2008 Apr 28.

PMID:
18503884
8.
9.

Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.

Cao Q, Wang L, Du F, Sheng H, Zhang Y, Wu J, Shen B, Shen T, Zhang J, Li D, Li N.

Cell Res. 2007 Jul;17(7):627-37.

10.

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS.

Gastroenterology. 2007 Jun;132(7):2328-39. Epub 2007 Apr 14.

PMID:
17570208
11.

A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.

Grille S, Brugnini A, Nese M, Corley E, Falkenberg FW, Lens D, Chabalgoity JA.

Cancer Immunol Immunother. 2010 Apr;59(4):519-27. doi: 10.1007/s00262-009-0768-6. Epub 2009 Sep 19.

PMID:
19768458
12.

Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.

Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N, Yamaguchi T, Sakaguchi S, Darcy PK, Smyth MJ.

Cancer Res. 2010 Apr 1;70(7):2665-74. doi: 10.1158/0008-5472.CAN-09-1574. Epub 2010 Mar 23.

13.

Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.

Kovar M, Tomala J, Chmelova H, Kovar L, Mrkvan T, Joskova R, Zakostelska Z, Etrych T, Strohalm J, Ulbrich K, Sirova M, Rihova B.

Cancer Res. 2008 Dec 1;68(23):9875-83. doi: 10.1158/0008-5472.CAN-08-1979.

15.

The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.

Javeed A, Zhang B, Qu Y, Zhang A, Sun C, Zhang L, Liu J, Zeng C, Zhao Y.

Transpl Immunol. 2009 Mar;20(4):253-60. doi: 10.1016/j.trim.2008.12.001. Epub 2009 Jan 13.

PMID:
19146957
16.

Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.

Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA.

Blood. 2008 Jun 1;111(11):5359-70. doi: 10.1182/blood-2007-08-105395. Epub 2008 Feb 27.

17.

Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.

He F, Chen Z, Xu S, Cai M, Wu M, Li H, Chen X.

Surgery. 2009 Jun;145(6):663-74. doi: 10.1016/j.surg.2009.01.016. Epub 2009 Apr 19.

PMID:
19486771
18.
19.

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation.

Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8. doi: 10.1073/pnas.0711106105. Epub 2008 Jul 17.

20.

Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.

Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H.

J Immunol. 2007 Sep 1;179(5):2860-9.

Supplemental Content

Support Center